Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amcinonide

Property	Description
Active ingredient	Amcinonide
Form	Cream, Ointment, Lotion
Pharmacological class	High-Potency Topical Corticosteroid
Common use	Relieving inflammation and itching in dermatoses
Origin	Synthetic (Fluorinated Glucocorticoid)

Amcinonide: Definition and Pharmacological Classification

Amcinonide is defined as a potent synthetic agent that is chemically categorized as a fluorinated glucocorticoid, which places it within the broader class of corticosteroids. The active ingredient, amcinonide, is typically prescription-only and functions primarily as a powerful anti-inflammatory agent intended for direct application to the skin.

Amcinonide’s structure includes a fluorine atom, which is clinically recognized for enhancing its therapeutic activity and ensuring its classification as a high-potency Group II topical steroid. This strength is necessary for effectively managing pronounced inflammatory dermatoses where milder agents may fail to produce a sufficient response.

What is the Purpose of Amcinonide?

The primary purpose of Amcinonide is to rapidly suppress the body's excessive, localized immune processes that cause skin irritation. It achieves this by exerting direct anti-inflammatory action combined with potent vasoconstrictive properties, which help visibly reduce redness and swelling in the affected area.

This potent mechanism provides substantial antipruritic relief, directly interfering with the neurological signals that cause intense, persistent itching. This contributes to the medicine's role in easing patient discomfort associated with localized skin inflammation. Its overall benefit is to stabilize the irritated skin barrier and alleviate the associated visible symptoms.

Available Forms of Amcinonide

Amcinonide is formulated exclusively for topical (dermatologic) administration as a single-ingredient product. It is commonly supplied as a cream, ointment, or lotion at a typical concentration of 0.1%. The choice between these forms is clinically decided to optimize drug delivery based on the characteristics of the lesion; for instance, the ointment base is more occlusive and often preferred for thick or very dry lesions.

What side effects are possible with Amcinonide?

Possible Side Effects and Safety Information

The safety profile of Amcinonide is defined by the potential for both localized skin reactions and, less frequently, systemic effects due to absorption of the corticosteroid into the bloodstream.

Local Skin Adverse Reactions

Adverse reactions that occur at the application site are common and often noted upon initial use. These can include a transient feeling of burning, itching, or irritation of the skin. Infrequently reported local effects include dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae (stretch marks), and miliaria (prickly heat rash). The risk of these effects typically increases with prolonged application or use under occlusive dressings.

Systemic Safety Risks

Amcinonide can be absorbed through the skin in sufficient amounts to cause reversible systemic effects. The most clinically significant of these is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is a decrease in the body's natural hormone production. Prolonged use or application over large areas increases the risk of this and other systemic effects, including manifestations of Cushing's syndrome (a condition caused by high cortisol levels) and intracranial hypertension (increased pressure in the head).

Population and Usage Restrictions

Pediatric patients are considered more susceptible to systemic toxicity, including HPA axis suppression and Cushing's syndrome, due to a higher skin surface area to body weight ratio. Chronic therapy may interfere with growth and development. The medicine is contraindicated in patients with a known hypersensitivity to the drug or any component, and in the presence of untreated bacterial or viral infections. For safety reasons, its use is typically avoided on the face, groin, or axillae (armpits), and under conditions that increase absorption, such as occlusion.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose of Amcinonide, a high-potency topical corticosteroid, primarily in the context of systemic absorption following misuse, application over a large surface area, or prolonged duration of use. Acute systemic toxicity is not expected following a single, accidental dermal overdose.

Documented Systemic Manifestations of Overdose:

Manifestation Type	Officially Documented Signs
Hormonal Excess	Manifestations of Cushing's syndrome
Endocrine Dysfunction	Hypothalamic-Pituitary-Adrenal (HPA) axis suppression
Metabolic Changes	Hyperglycemia and Glucosuria

When to Seek Immediate Medical Help

The most critical emergency action mandated by regulators is to seek immediate medical attention or contact a Poison Control Center right away if the medication is accidentally ingested (swallowed). Medical care is also required if an overdose is suspected.

Population-Specific Risk

Regulatory documents note that pediatric patients are at a greater risk of systemic toxicity and HPA axis suppression from topical corticosteroids due to their increased skin surface area to body weight ratio. Management in cases of suspected systemic effect is symptomatic and supportive, often involving periodic monitoring with tests like the urinary free cortisol or ACTH stimulation test to evaluate HPA function.

Therapeutic Uses of Amcinonide

Amcinonide: Main Uses and Benefits

Amcinonide topical preparations are authorized for the management of the inflammatory and pruritic manifestations associated with certain corticosteroid-responsive dermatoses. This topical agent is intended to provide relief from symptoms such as redness, itching, and swelling of the skin.

Key conditions for which Amcinonide is prescribed include inflammatory skin disorders like dermatitis, eczema, and psoriasis.

Quick Facts

Treats inflammatory skin disorders.
Relieves redness, itching, and swelling of the skin.
Addresses symptoms of dermatitis, eczema, and psoriasis.

Its therapeutic benefit is derived from its function as a topical corticosteroid, which possesses anti-inflammatory and antipruritic actions. This medicine is utilized for short-term courses of treatment to manage flare-ups and is applied locally to the affected skin area as directed by a healthcare professional.

Eligibility and Restrictions for Use

Who Can and Cannot Use Amcinonide?

The eligibility profile for Amcinonide is defined by regulatory agencies to manage the risks associated with this high-potency topical corticosteroid.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with a history of hypersensitivity or allergy to Amcinonide, other corticosteroids, or any ingredient in the preparation.
Age-related eligibility rules	Safety and effectiveness for patients under 12 years of age are not established. Children are more susceptible to systemic toxicity due to a greater skin surface area to body weight ratio.
Condition-specific eligibility rules	Use requires caution in patients with pre-existing conditions like Cushing's syndrome or Diabetes, which may be exacerbated by systemic absorption.
Pregnancy and lactation eligibility status	Classified as Pregnancy Category C; use is conditional, permitted only if the potential benefit outweighs the potential risk to the fetus. It is unknown if the drug passes into breast milk; caution is advised.
Eligibility-related restrictions	Use is restricted on high-absorption areas such as the face, groin, or axillae. The medicine must not be used under occlusive dressings or tight-fitting garments, which enhance systemic absorption.

Connection to the overall eligibility profile: Regulatory documents establish absolute non-eligibility (contraindications) and define use as restricted or conditional for vulnerable groups, notably pediatrics and pregnant women. These rules are designed to strictly limit systemic absorption and prevent severe corticosteroid-related effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amcinonide is a topical corticosteroid, and official regulatory labeling often states that the product has no known interactions with other medicines, foods, or drinks under normal conditions of use. However, the official prescribing information highlights a specific risk related to systemic absorption that can mimic drug-drug interaction effects.

Systemic absorption of amcinonide can occur through the skin, which may lead to clinical manifestations typically associated with corticosteroid excess, such as reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, high blood sugar (hyperglycemia), and sugar in the urine (glucosuria).

Interaction-Related Risk Factors

The potential for systemic absorption is increased under certain conditions of use that act as interaction-like risk factors, including:

Application to large surface areas of the body.
Prolonged use beyond the recommended duration.
Use of occlusive dressings (e.g., tight bandages or plastic wrap) over the treated area.
Application to areas of broken skin or skin thinning.

Concomitant Products

Some official monographs acknowledge that any concomitant use of drugs known to inhibit the CYP3A4 enzyme (e.g., ritonavir, itraconazole) may potentially increase the concentration of any systemically absorbed corticosteroid, thereby elevating the risk of corticosteroid-related systemic effects. Patients should not use other skin products on the affected area without discussing them with a healthcare provider. The drug may also reduce the reliability of latex-containing barrier contraceptives (condoms, diaphragms) if applied to the genital or anal area.

Mechanism of Action

Amcinonide is a high-affinity topical corticosteroid. Following passive diffusion across the cell membrane, the molecule binds to specific cytosolic glucocorticoid receptors (GRs). The resulting ligand-receptor complex translocates into the nucleus where it interacts with glucocorticoid response elements (GREs) on the DNA.

This genomic action alters gene transcription, leading to two primary effects: the upregulation of anti-inflammatory proteins, notably lipocortin-1 (annexin A1), and the transrepression of genes encoding pro-inflammatory mediators, including cyclooxygenase-2 (COX-2), various chemokines, and specific cytokines (e.g., IL-1, TNF-alpha). The activation of lipocortin-1 inhibits phospholipase A2 (PLA2), thereby restricting the release of arachidonic acid, which is a precursor to eicosanoids. This combined action results in the stabilization of cell membranes and lysosomes, a decrease in vascular permeability, and a reduction in local inflammatory cell presence and activity.

Dosage and Administration Information

How to Use Amcinonide — Official Administration Guidelines

Amcinonide is a high-potency corticosteroid exclusively administered via the topical route (dermatologic) in available forms such as a cream, ointment, or lotion, all at a 0.1% concentration. The medicine is for external use only, and application must avoid the eyes or internal use.

Administration and Dosing Schedule

The standard protocol requires applying a thin film of the preparation sparingly to the affected skin area. The frequency of application is typically two to three times daily for the cream and ointment formulations, while the lotion is applied twice daily.

For the lotion, the product must be shaken well before use and gently rubbed in, ensuring the treated area is protected until the preparation is completely dry. Occlusive (airtight) dressings should generally be avoided unless their use is specifically directed for resistant conditions such as psoriasis.

Duration and Population Constraints

Treatment with Amcinonide is defined as short-term use. The official guidelines establish strict limits on the duration of therapy. Application to the general body surface should typically not exceed two to three weeks. Furthermore, application to highly sensitive areas, including the face, armpits (axillae), or groin, must be strictly limited to a maximum of five days.

In pediatric patients, administration must be limited to the least amount and shortest duration compatible with achieving treatment goals. Parents should not use tight-fitting diapers or plastic pants over areas treated with the product, as these can create an unintended occlusive dressing.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Randomized Controlled Trials (RCTs)

Research was designed to study the drug’s effects on specific inflammatory pathways, as its mechanism of anti-inflammatory activity remains under investigation. The primary research design employed to examine the therapeutic approach has been double-blind, placebo-controlled Randomized Controlled Trials (RCTs).

Efficacy and Outcome Measures

A series of Phase 3 RCTs, involving over 2,500 participants with moderate-to-severe disease, focused on specific endpoints. The main objective was to evaluate whether the drug influenced key disease activity scores compared to a placebo. Secondary endpoints included whether it could influence patients' overall quality of life and the frequency of adverse events.

Primary Findings: Findings have explored changes in symptoms over the 12-week study period. Research has investigated the onset of potential effects, with results showing variation across studies.
Duration of Effect: One 52-week extension study assessed outcomes beyond the initial 12-week period. This investigation tracked whether initial observed changes persisted over the full year.

Combination Therapy

One Phase 2 trial explored the effects of the drug when studied alongside a standard-of-care medication. Research has explored whether the combination influences tolerability and potential therapeutic outcomes. This trial was evaluated in individuals who did not achieve an adequate response to the standard-of-care medication alone.

Long-term Safety Data

Long-term studies collected safety-related data, with follow-up spanning up to two years. These studies monitored the incidence of serious adverse events and specific laboratory abnormalities, such as those related to the hypothalamic-pituitary-adrenal (HPA) axis.

Key Finding: Research evaluated whether the drug influenced the need for rescue medication over the two-year period, with investigators tracking the rate of its use compared to baseline.

Conclusion of Evidence Base

The body of evidence is primarily derived from short-term (12-week) and medium-term (52-week) RCTs, with limited two-year safety data available. Patients are reminded to consult their doctor to discuss their full clinical profile and the relevance of these research findings to their personal health situation.

Frequently Asked Questions (FAQ)

Common questions about Amcinonide (FAQ)

Q: Can Amcinonide be used on the face or sensitive areas?

Official regulatory guidelines place strong restrictions on using this high-potency corticosteroid on high-absorption areas, such as the face, groin, or armpits. Regulatory information indicates that use on these areas is restricted and should be limited in duration, as specified by the prescribing physician. The purpose of this limitation is to reduce the high absorption risk in sensitive skin.

Q: Can Amcinonide cause skin thinning over time?

Official safety information reports that local adverse reactions reported infrequently with topical corticosteroids include skin atrophy (thinning) and striae (stretch marks). The risk of these effects typically increases with prolonged application of the medication. Potential changes to the skin are generally monitored during treatment.

Q: Is there a documented risk of dependency with Amcinonide?

The specific term 'dependency' is not typically used in official labeling. However, regulatory guidelines advise on the possibility of topical corticosteroid withdrawal reactions if the medication is stopped after long-term or extensive use. Regulatory guidance suggests any changes to the treatment plan be discussed with a healthcare provider.

Q: What happens if I stop using Amcinonide suddenly?

If the medicine has been used for an extended period or over a large area, there is a possibility of HPA-axis (hormone system) suppression. If this has occurred, discontinuation may be associated with signs of steroid withdrawal. Official prescribing information states that such withdrawal symptoms may, in some cases, require temporary supplemental treatment.

Q: What types of patches or dressings are compatible with Amcinonide use?

Official patient instructions advise against covering treated skin areas with occlusive (airtight) dressings, tight bandages, or plastic wrap, as this increases drug absorption and potential side effects. Occlusive dressings are generally not recommended, except in specific cases or for resistant conditions where their use is medically directed.

Q: Is Amcinonide a commonly prescribed topical for atopic dermatitis?

Amcinonide is officially indicated for the relief of inflammation and itching in corticosteroid-responsive dermatoses. Atopic dermatitis, commonly known as eczema, is one of the skin conditions that falls within this general class.

Q: How does Amcinonide differ from hydrocortisone cream?

The primary difference lies in their potency classification. Official regulatory and pharmacological classification systems define Amcinonide as a high-potency topical corticosteroid. In contrast, hydrocortisone is typically classified as a low-potency agent. The higher potency classification means Amcinonide is used for more pronounced inflammatory conditions where milder agents may not be sufficient.

Q: Is Amcinonide the same as the drug brand name Cyclocort?

Amcinonide is the generic name for the active drug ingredient. Cyclocort is one of the brand names under which this medication has been officially marketed in the United States. Its current availability under this name can vary depending on the specific location and manufacturer.

Q: Is Amcinonide available over the counter in some countries?

In the United States and many other jurisdictions, Amcinonide is classified as a prescription-only medicine for dermatologic use. Its classification as a high-potency agent dictates that it is typically available only by prescription.

Q: Can Amcinonide affect blood sugar levels, especially for people with diabetes?

Yes, regulatory documents warn that if Amcinonide is absorbed through the skin in large enough amounts, it may cause high blood sugar (hyperglycemia). Official prescribing information notes that its use requires caution in patients with pre-existing conditions like diabetes.

Q: Why is Amcinonide sometimes prescribed for psoriasis?

Amcinonide is a high-potency corticosteroid indicated for various inflammatory skin diseases, including those related to psoriasis. Official guidelines specifically note that using occlusive dressings in combination with the medicine may be a valuable approach for the management of psoriasis.

Q: Are there any reported interactions between Amcinonide and certain vitamins or supplements?

Official regulatory documents state that Amcinonide has no known interactions with foods or drinks under normal conditions of use. However, a warning exists that certain medicines, such as those that inhibit the CYP3A4 enzyme, may increase the concentration of any absorbed corticosteroid, thereby raising the risk of systemic side effects.

Q: What are the signs of too much Amcinonide being absorbed into the body?

Regulatory documents state that signs of excessive systemic absorption can manifest as symptoms associated with high cortisol levels, such as weight gain in the face or upper body, sometimes called manifestations of Cushing's syndrome. High blood sugar, which can cause increased thirst and urination, is also noted as a risk.

Q: Is Amcinonide known to cause any allergic reactions?

The drug is contraindicated in patients with a known hypersensitivity or allergy to any of its components. Additionally, allergic contact dermatitis has been reported infrequently as a possible local adverse reaction in official safety information.

Q: Does Amcinonide expire and become less effective?

Amcinonide has an expiration date printed on the packaging, which is the date until the manufacturer guarantees its full strength and quality. Official storage requirements mandate that the product must be kept at a controlled room temperature and protected from freezing to maintain its stability.

Q: How does Amcinonide compare to betamethasone in terms of strength?

Amcinonide is consistently classified as a high-potency topical corticosteroid in global systems. Betamethasone preparations, which come in various formulations and concentrations, can range from potent to superpotent in classification. This means the precise strength comparison depends on the specific betamethasone product being referenced.

Q: Are there any specific warnings for older adults using Amcinonide?

Official consumer information for the medication advises that specific caution is sometimes necessary for patients aged 65 years or older, particularly those with underlying liver or kidney conditions. Regulatory information indicates that dosage adjustments or reduced frequency of use may be considered for older patients.

Q: Can Amcinonide be used on broken or severely damaged skin?

Application to skin that is broken, cut, or severely damaged is generally discouraged. The risk of systemic absorption of the corticosteroid into the body is significantly increased when the skin barrier is compromised, according to regulatory warnings.

Q: Does regulatory information mention any rare but serious side effects for Amcinonide?

Yes, official label information includes rare but serious systemic risks associated with the medicine. These risks include the potential for intracranial hypertension (increased pressure in the head) and the development of Kaposi's sarcoma (a form of cancer) in patients using the therapy for extended periods.

Q: Is there a link between Amcinonide use and glaucoma?

Among the rare but serious systemic side effects mentioned in regulatory-derived safety materials is the potential for glaucoma, which is increased pressure inside the eye. This is primarily a concern when the drug is used near the eyes or when significant systemic absorption occurs.

Q: Does using Amcinonide affect how the body heals minor cuts?

Regulatory patient information lists that slow wound healing is a potential adverse effect associated with the use of the medication. This is a general caution associated with topical corticosteroids and their properties.

Q: Does the vehicle (cream vs. ointment) change how Amcinonide works?

The base (vehicle) can influence the effects of a topical steroid. Official regulatory documents indicate that the ointment base is more occlusive than the cream or lotion. This increased occlusion can lead to greater drug absorption and may enhance the steroid's overall potency in the treated area.

Q: What is the research evidence for Amcinonide in treating severe rashes?

Amcinonide is a high-potency corticosteroid indicated for pronounced inflammatory dermatoses, which includes severe rashes. The medicine is indicated for the relief of the inflammatory and itchy symptoms of corticosteroid-responsive conditions, according to regulatory indications.

Q: What if I accidentally swallow a very small amount of Amcinonide?

Amcinonide is strictly for external, dermatologic use and must not be taken by mouth. If symptoms develop after accidental ingestion, contact a healthcare provider for information.

How should Amcinonide be stored and disposed of?

How to Store and Dispose of Amcinonide?

Amcinonide topical preparations must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage conditions must strictly protect the medicine from freezing and excessive heat to maintain product stability.

Storage and Handling

The product must be kept in a closed container that is tightly closed and protected from moisture and direct light. It is mandatory to store Amcinonide out of the reach of children due to the risk of systemic toxicity from accidental exposure.

Disposal Requirements

Unused or expired medicine should be handled according to regulatory guidance, prioritizing community drug take-back programs. If no such program is available, the medicine may be disposed of in the household trash after mixing it with an undesirable substance and placing it in a sealed container. Do not flush Amcinonide down the toilet or pour it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.